je.st
news
Tag: infection
Increasing soybean meal in diet may play role in battling infection in weanling pigs
2015-09-17 18:08:00| National Hog Farmer
Source: University of Illinois University of Illinois has found that increasing concentrations of soybean meal (SBM) in the diets of weanling pigs, above industry standards, may be beneficial for pigs that are infected with the porcine reproductive and respiratory syndrome virus (PRRSV). read more
Tags: play
role
increasing
diet
Awareness Raised of Mild Infection that Resembles FMD
2015-09-04 02:00:00| ThePigSite - Industry News
CANADA - The executive director of the US based Swine Health Information Centre is advising pork producers to be on the watch for signs of Seneca Valley Virus, writes Bruce Cochrane.
Tags: raised
awareness
infection
mild
How much will a trich infection cost you? The numbers arent pretty
2015-07-30 16:23:00| Beef
Trich is a silent thiefsilent, that is, until a rancher with a herd chronically infected with trich realizes just how much money could have been pocketed if the herd was clean. Heres a look at the numbers. read more
Merck Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Grazoprevir/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Genotypes 1, 4 and 6 Infection
2015-07-28 12:30:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Company Granted FDA Priority Review with Target Action Date of January 28, 2016 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Language: English Contact: MerckMedia:Doris Li, (908) 246-5701Sarra Herzog, (201) 669-6570orInvestor:Joe Romanelli, (908) 740-1986Justin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: and
food
application
administration
Merck Announces European Medicines Agency Acceptance of Marketing Authorization Application for Grazoprevir/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Infection
2015-07-23 17:02:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a marketing authorization application (MAA) for grazoprevir/elbasvir (100mg/50mg), an investigational, once-daily, single-tablet combination therapy for the treatment of adult patients with chronic hepatitis C (HCV) genotypes (GT) 1, 3, 4 or 6 infection.1 The EMA will initiate review of the MAA under accelerated assessment timelines. Language: English Contact: Merck & Co., Inc.Media:Doris Li, 908-246-5701orSarra Herzog, 201-669-6570orInvestor:Joe Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: of
application
marketing
treatment
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] next »